SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 12-Month High – Here’s What Happened

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $9.70 and last traded at $9.91, with a volume of 1591746 shares. The stock had previously closed at $9.17.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SLS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market cap of $2.44 billion, a P/E ratio of -53.87 and a beta of 2.50. The firm’s 50-day moving average is $7.14 and its two-hundred day moving average is $5.16.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Larson Financial Group LLC acquired a new position in SELLAS Life Sciences Group in the 4th quarter valued at $26,000. California State Teachers Retirement System grew its position in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares in the last quarter. Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group during the fourth quarter worth approximately $38,000. Concurrent Investment Advisors LLC bought a new position in SELLAS Life Sciences Group during the 4th quarter worth $38,000. Finally, Money Concepts Capital Corp acquired a new position in SELLAS Life Sciences Group in the 4th quarter valued at $40,000. 17.38% of the stock is currently owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.